Watch for Mix-Ups With the New COPD Three-Drug Inhaler Combo Trelegy Ellipta

January 2018

Trelegy Ellipta (TREL-eh-gee) will be the first "three-in-one" inhaler for COPD.

It contains the long-acting muscarinic antagonist (LAMA) umeclidinium...the long-acting beta-agonist (LABA) vilanterol...and the inhaled corticosteroid (ICS) fluticasone furoate.

Trelegy is a dry-powder inhaler given as a single puff once daily.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Shortages Use Creative Strategies to Conserve IV Fluids During Shortages
Infectious Diseases Help Reduce Empiric Broad-Spectrum Antibiotic Use for Skin Infections
Neurology Pain Weigh the Pros and Cons of Using IV Lidocaine for Pain
Influenza Stick With Oseltamivir to Treat Hospitalized Flu Patients
New Drugs Watch for Mix-Ups With the New COPD Three-Drug Inhaler Combo Trelegy Ellipta
Substance Use Disorder Know How to Treat Acute Pain in Patients Taking Meds for Opioid Dependence
Hypertension Expect More Patients to Be on Antihypertensives at Home
Hypothyroidism Discourage Routinely Checking TSH Levels in Hospitalized Patients
Diabetes Meds Ensure Safe Use of Sulfonylureas for Type 2 Diabetes
Med Safety Educate Discharge Patients About Meds Linked to Driving Impairment
New Drugs Watch for Mix-Ups With the New COPD Three-Drug Inhaler Combo Trelegy Ellipta

Watch for Mix-Ups With the New COPD Three-Drug Inhaler Combo Trelegy Ellipta

Get unlimited access through an Enterprise license

Table of Contents